Skip to main content
Top
Published in: Tumor Biology 4/2013

01-08-2013 | Research Article

HFE gene C282Y variant is associated with colorectal cancer in Caucasians: a meta-analysis

Authors: Weidong Chen, Hua Zhao, Tiegang Li, Hongliang Yao

Published in: Tumor Biology | Issue 4/2013

Login to get access

Abstract

The HFE gene has been suggested to play an important role in the pathogenesis of colorectal cancer. However, the results have been conflicting. In this study, we performed a meta-analysis to clarify the association of HFE gene C282Y variant with colorectal cancer. PubMed and Embase were retrieved to identify the potential literature. Pooled odds ratio (OR) with 95 % confidence interval (CI) was calculated using fixed- or random-effects model. A total of eight papers including nine studies (7,588 colorectal cancer cases and 81,571 controls) for HFE gene C282Y variant were included in the meta-analysis. The result indicated that HFE gene C282Y variant was significantly associated with colorectal cancer under recessive model (OR = 2.00, 95 % CI = 1.32–3.04), with no evidence of between-study heterogeneity (I 2 = 0.2 %, p = 0.432). Further subgroup analysis by number of cases suggested the effect was significant in studies with more than 500 cases (OR = 2.51, 95 % CI = 1.58–3.98, I 2 = 0.0 %, p = 0.921), but not in studies with less than 500 cases (OR = 0.75, 95 % CI = 0.28–1.97, I 2 = 0.0 %, p = 0.622). The current meta-analysis supported the positive association of HFE gene C282Y variant with colorectal cancer. Further large-scale studies with the consideration for gene–gene/gene–environment interactions should be conducted to investigate the association.
Literature
1.
go back to reference Chua AC, Klopcic B, Lawrance IC, Olynyk JK, Trinder D. Iron: an emerging factor in colorectal carcinogenesis. World J Gastroenterol. 2010;16:663–72.PubMedCrossRef Chua AC, Klopcic B, Lawrance IC, Olynyk JK, Trinder D. Iron: an emerging factor in colorectal carcinogenesis. World J Gastroenterol. 2010;16:663–72.PubMedCrossRef
2.
3.
go back to reference Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med. 2000;133:329–37.PubMedCrossRef Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med. 2000;133:329–37.PubMedCrossRef
4.
go back to reference Beckman LE, Van Landeghem GF, Sikström C, Wahlin A, Markevärn B, Hallmans G, et al. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis. 1999;20:1231–3.PubMedCrossRef Beckman LE, Van Landeghem GF, Sikström C, Wahlin A, Markevärn B, Hallmans G, et al. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis. 1999;20:1231–3.PubMedCrossRef
5.
go back to reference Shaheen NJ, Silverman LM, Keku T, Lawrence LB, Rohlfs EM, Martin CF, et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003;95:154–9.PubMedCrossRef Shaheen NJ, Silverman LM, Keku T, Lawrence LB, Rohlfs EM, Martin CF, et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003;95:154–9.PubMedCrossRef
6.
go back to reference Vander A DL, van der Hel O, Roest M, Vander Schouw YT, van Gils CH, Marx JJ, et al. Heterozygosity for the Cys282Tyr mutation in the HFE gene and the risk of colorectal cancer (Netherlands). Cancer Causes Control. 2003;14(6):541–5.CrossRef Vander A DL, van der Hel O, Roest M, Vander Schouw YT, van Gils CH, Marx JJ, et al. Heterozygosity for the Cys282Tyr mutation in the HFE gene and the risk of colorectal cancer (Netherlands). Cancer Causes Control. 2003;14(6):541–5.CrossRef
7.
go back to reference McGlynn KA, Sakoda LC, Hu Y, Schoen RE, Bresalier RS, Yeager M, et al. Hemochromatosis gene mutations and distal adenomatous colorectal polyps. Cancer Epidemiol Biomarkers Prev. 2005;14(1):158–63.PubMed McGlynn KA, Sakoda LC, Hu Y, Schoen RE, Bresalier RS, Yeager M, et al. Hemochromatosis gene mutations and distal adenomatous colorectal polyps. Cancer Epidemiol Biomarkers Prev. 2005;14(1):158–63.PubMed
8.
go back to reference Robinson JP, Johnson VL, Rogers PA, Houlston RS, Maher ER, Bishop DT, et al. Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(6):1460–3.PubMedCrossRef Robinson JP, Johnson VL, Rogers PA, Houlston RS, Maher ER, Bishop DT, et al. Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(6):1460–3.PubMedCrossRef
9.
go back to reference Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010;51(4):1311–8.PubMedCrossRef Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010;51(4):1311–8.PubMedCrossRef
10.
go back to reference Ekblom K, Marklund SL, Palmqvist R, Van Guelpen B, Hallmans G, Weinehall L, et al. Iron biomarkers in plasma, HFE genotypes, and the risk for colorectal cancer in a prospective setting. Dis Colon Rectum. 2012;55(3):337–44.PubMedCrossRef Ekblom K, Marklund SL, Palmqvist R, Van Guelpen B, Hallmans G, Weinehall L, et al. Iron biomarkers in plasma, HFE genotypes, and the risk for colorectal cancer in a prospective setting. Dis Colon Rectum. 2012;55(3):337–44.PubMedCrossRef
11.
go back to reference Asberg A, Thorstensen K, Irgens WØ, Romundstad PR, Hveem K. Cancer risk in HFE C282Y homozygotes: results from the HUNT 2 study. Scand J Gastroenterol. 2013;48(2):189–95.PubMedCrossRef Asberg A, Thorstensen K, Irgens WØ, Romundstad PR, Hveem K. Cancer risk in HFE C282Y homozygotes: results from the HUNT 2 study. Scand J Gastroenterol. 2013;48(2):189–95.PubMedCrossRef
12.
go back to reference Altés A, Gimferrer E, Capella G, Barceló MJ, Baiget M. Colorectal cancer and HFE gene mutations. Haematologica. 1999;84(5):479–80.PubMed Altés A, Gimferrer E, Capella G, Barceló MJ, Baiget M. Colorectal cancer and HFE gene mutations. Haematologica. 1999;84(5):479–80.PubMed
13.
go back to reference Macdonald GA, Tarish J, Whitehall VJ, McCann SJ, Mellick GD, Buttenshaw RL, et al. No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. J Gastroenterol Hepatol. 1999;14(12):1188–91.PubMedCrossRef Macdonald GA, Tarish J, Whitehall VJ, McCann SJ, Mellick GD, Buttenshaw RL, et al. No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. J Gastroenterol Hepatol. 1999;14(12):1188–91.PubMedCrossRef
14.
go back to reference Shi Z, Johnstone D, Talseth-Palmer BA, Evans TJ, Spigelman AD, Groombridge C, et al. Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Int J Cancer. 2009;125(1):78–83.PubMedCrossRef Shi Z, Johnstone D, Talseth-Palmer BA, Evans TJ, Spigelman AD, Groombridge C, et al. Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Int J Cancer. 2009;125(1):78–83.PubMedCrossRef
15.
16.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
17.
go back to reference Fargion S, Valenti L, Fracanzani AL. Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overload. Hepatology. 2010;51(4):1119–21.PubMedCrossRef Fargion S, Valenti L, Fracanzani AL. Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overload. Hepatology. 2010;51(4):1119–21.PubMedCrossRef
18.
go back to reference Sullivan JL. Re: Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003;95(11):829–30.PubMedCrossRef Sullivan JL. Re: Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003;95(11):829–30.PubMedCrossRef
19.
go back to reference Chan AT, Ma J, Tranah GJ, Giovannucci EL, Rifai N, Hunter DJ, et al. Hemochromatosis gene mutations, body iron stores, dietary iron, and risk of colorectal adenoma in women. J Natl Cancer Inst. 2005;97(12):917–26.PubMedCrossRef Chan AT, Ma J, Tranah GJ, Giovannucci EL, Rifai N, Hunter DJ, et al. Hemochromatosis gene mutations, body iron stores, dietary iron, and risk of colorectal adenoma in women. J Natl Cancer Inst. 2005;97(12):917–26.PubMedCrossRef
20.
go back to reference Thaler RH. The winner's curse paradoxes and anomalies of economic life. Princeton, NJ: Princeton University Press; 1999. Thaler RH. The winner's curse paradoxes and anomalies of economic life. Princeton, NJ: Princeton University Press; 1999.
21.
go back to reference Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology. 2007;46(4):1071–80.PubMedCrossRef Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology. 2007;46(4):1071–80.PubMedCrossRef
22.
go back to reference Jin F, Qu LS, Shen XZ. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exp Clin Cancer Res. 2010;29:18.PubMedCrossRef Jin F, Qu LS, Shen XZ. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exp Clin Cancer Res. 2010;29:18.PubMedCrossRef
23.
go back to reference Jin F, Xiong WJ, Jing JC, Feng Z, Qu LS, Shen XZ. Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J Cancer Res Clin Oncol. 2011;137(7):1095–104.PubMedCrossRef Jin F, Xiong WJ, Jing JC, Feng Z, Qu LS, Shen XZ. Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J Cancer Res Clin Oncol. 2011;137(7):1095–104.PubMedCrossRef
Metadata
Title
HFE gene C282Y variant is associated with colorectal cancer in Caucasians: a meta-analysis
Authors
Weidong Chen
Hua Zhao
Tiegang Li
Hongliang Yao
Publication date
01-08-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0766-3

Other articles of this Issue 4/2013

Tumor Biology 4/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine